3:43 PM
 | 
May 15, 2019
 |  BC Extra  |  Company News

May 15 Company Quick Takes: Approvals for Bavencio in RCC, Venclexta-Gazyva combo; plus Adaptimmune, Alpine, Advaxis

Bavencio gets RCC approval with Inlyta
FDA approved Bavencio avelumab from Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) for first-line treatment of advanced renal cell carcinoma in combination with Pfizer's Inlyta axitinib, making Bavencio the first anti-PD-L1 therapy approved for the indication. Inlyta is approved for the same indication in combination with anti-PD-1 Keytruda pembrolizumab (see “Keytruda Combo Gains...

Read the full 273 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >